Results 51 to 60 of about 25,648 (169)

Minimal residual disease is an independent predictor for 10-year survival in CLL [PDF]

, 2016
Minimal residual disease (MRD) negativity, defined as
Abraham Varghese, Abrisqueta, Andy C. Rawstron, Bosch, Böttcher, Chi Doughty, Darren J. Newton, Dreger, Eichhorst, Fischer, Goede, Hallek, Landau, Ma, Marwan Kwok, Moreno, Moreton, Nadeu, Paul A. S. Evans, Paul Moreton, Peter Hillmen, Pettitt, Rawstron, Rawstron, Rawstron, Rossi, Santacruz, Sheila J. M. O’Connor, Strati, Thompson   +29 more
core   +1 more source

Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia

Cell Death and Disease
Venetoclax, a selective BCL2 inhibitor, is extensively utilized in clinical settings for the treatment of acute myeloid leukemia (AML). However, its efficacy is often compromised by the development of drug resistance.
Chang-qing Jiao, Chen Hu, Meng-hua Sun, Yan Li, Chao Wu, Fei Xu, Lei Zhang, Fu-rong Huang, Jun-jie Zhou, Ji-fei Dai, Min Ruan, Wen-chao Wang, Qing-song Liu, Jian Ge   +13 more
doaj   +1 more source

CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator

Cell Death and Disease
BCL-2 inhibitors such as venetoclax offer therapeutic promise in acute myeloid leukemia (AML) and other cancers, but drug resistance poses a significant challenge. It is crucial to understand the mechanisms that regulate venetoclax response.
Lixia Zhang, Xinyue Zhou, Sajesan Aryal, Virginia Veasey, Pengcheng Zhang, Fu Jun Li, Yu Luan, Ravi Bhatia, Yang Zhou, Rui Lu   +9 more
doaj   +1 more source

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Haematologica, 2018
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia ...
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan   +47 more
doaj   +1 more source

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models

Cancer Medicine, 2021
Purpose Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with ...
Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova   +5 more
doaj   +1 more source

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis [PDF]

, 2017
The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies.
Butterworth, Michael, Byrne, Dominic P, Cohen, Gerald M, Eyers, Patrick A, Greaves, Georgia, Milani, Mateus, Varadarajan, Shankar   +6 more
core   +2 more sources

Estudio de utilización de Ibrutinib en leucemia linfocítica crónica [PDF]

, 2019
La leucemia linfocítica crónica (LLC) es la leucemia más frecuente en nuestro país afectando mayoritariamente a mayores de 65 años. En los últimos años el tratamiento de la leucemia linfocítica crónica se ha visto modificado debido al ...
Beltrán Gómez, Inés
core  

Current perspectives in fragment based lead discovery (FBLD) [PDF]

, 2017
It is over 20 years since the first fragment-based discovery projects were disclosed. The methods are now mature for most ‘conventional’ targets in drug discovery such as enzymes (kinases and proteases) but there has also been growing success on more ...
Alvarez-Garcia, Bas Lamoree, Baurin, Bertrand, Boehm, Bollag, Chen, Chen, Congreve, Darby, Davies, English, Erlanson, Erlanson, Erlanson, Fischer, Giannetti, Goodford, Gossert, Hajduk, Hajduk, Hajduk, Hann, Hopkins, Howard, Hubbard, Hubbard, Hubbard, Hubbard, Jencks, Johnson, Keseru, Kozakov, Lau, Linke, Ludlow, Maurer, Meiby, Miller, Miranker, Nasiri, Nienaber, Oltersdorf, Ostrem, Parker, Paul Workman, Pearce, Renaud, Ringe, Rob L.M. van Montfort, Roderick E. Hubbard, Roughley, Ruiz-Carmona, Schiebel, Schiebel, Schulz, Shuker, Souers, Sun, Vivat   +59 more
core   +1 more source

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia
: The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax.
Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids   +13 more
doaj   +1 more source

On BH3 mimetics and Ca2+ signaling [PDF]

, 2017
BH3 mimetics are anticancer agents that reproduce the spatial arrangement of the BH3 domain of Bcl-2 family proteins. Just like the BH3-only proteins, these compounds bind to the hydrophobic cleft of the pro-survival Bcl-2 members such as Bcl-2 or Bcl-xL,
Ferdek, Pawel, Jakubowska, Monika
core   +1 more source